Subscribe to RSS
Download PDF
DOI: 10.1055/s-0044-1778723
Multiple Primary Malignancies and Bilateral Vocal Cord Paralysis Confusing the Management of Each Other
Abstract
Double primary malignancy though uncommon, we often encounter in our clinical practice. The lung malignancy is known to cause left vocal cord paralysis. Bilateral abductor paralysis secondary to adenocarcinoma of the lung with concurrent basal cell carcinoma of the face is not common. Proper counseling and timely management are needed in these cases of multiple primary malignancies. Early evaluation in all cases of hoarseness can help in early diagnosis and management.
Patient Consent
Patient's consent is taken.
Publication History
Article published online:
22 January 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Vaslamatzis M, Alevizopoulos N, Petraki C. et al. Second primary neoplasms (SPN) in cancer patients. Proc ASCO 2003; 22: 3581
- 2 Morgenfeld EL, Tognelli GF, Deza E. et al. Synchronous and metachronous second (ST) and third (TT) primary tumors (PT) in a large patient population. Proc ASCO 2003; 22: 3152
- 3 Hulikal N, Ray S, Thomas J, Fernandes DJ. Second primary malignant neoplasms: a clinicopathological analysis from a cancer centre in India. Asian Pac J Cancer Prev 2012; 13 (12) 6087-6091
- 4 Irimie A, Achimas-Cadariu P, Burz C, Puscas E. Multiple primary malignancies–epidemiological analysis at a single tertiary institution. J Gastrointestin Liver Dis 2010; 19 (01) 69-73
- 5 Bugher JC. The probability of the chance occurrence of multiple malignant neoplasms. Cancer Res 1934; 21 (04) 809-824
- 6 Amer MH. Multiple neoplasms, single primaries, and patient survival. Cancer Manag Res 2014; 6 (06) 119-134
- 7 Bagri PK, Singh D, Singhal MK. et al. Double primary malignancies: a clinical & pathological analysis report from a regional cancer institute in India. Iran J Cancer Prev 2014; 7 (02) 66-72
- 8 Curtis RE, Freedman DM, Ron E. et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000. NIH Publ. No. 05–5302. Bethesda, MD: National Cancer Institute; 2006
- 9 Hajdu SI, Hajdu EO. Multiple primary malignant tumors. J Am Geriatr Soc 1968; 16 (01) 16-26
- 10 Berge T, Cederqvist L, Schönebeck J. Multiple primary malignant tumours. An autopsy study of a circumscribed population. Acta Pathol Microbiol Scand 1969; 76 (02) 171-183
- 11 Vyas JJ, Deshpande RK, Sharma S, Desai PB. Multiple primary cancers in Indian population: metachronous and synchronous lesions. J Surg Oncol 1983; 23 (04) 239-249
- 12 Lv M, Zhang X, Shen Y. et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine (Baltimore) 2017; 96 (17) e6799
- 13 Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005; 353 (21) 2262-2269
- 14 Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. I. Introduction and presentation of data. Cancer 1961; 14: 221-230
- 15 Beyreuther H. Multiplicität von Carcinomen bei einem Fall von sog.“Schneeberger” Lungenkrebs mit Tuberkulose. Virchows Arch Pathol Anat Physiol Klin Med 1924; 250: 230-243
- 16 Wakejima R, Inamura K, Ninomiya H. et al. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma. Pathol Int 2020; 70 (02) 72-83
- 17 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72 (01) 7-33
- 18 Lindeman NI, Cagle PT, Aisner DL. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 2018; 13 (03) 323-358
- 19 Mino-Kenudson M. Immunohistochemistry in anaplastic lymphoma kinase and proto-oncogene tyrosine-protein kinase ROS. Arch Pathol Lab Med 2018; 142 (07) 792-793
- 20 Chowdary T, Sivaraj SM, Rao GV. et al. Dual malignancies: do they have a worse prognosis than their individual counterparts. Arch Int Surg 2015; 5: 29-32
- 21 Vogt A, Schmid S, Heinimann K. et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2017; 2 (02) e000172